Anixa Biosciences, Inc. ANIX
NASDAQ
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.15M | 6.12M | 6.41M | 6.63M | 6.58M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.98M | 10.68M | 11.03M | 11.70M | 11.99M |
| Operating Income | -10.98M | -10.68M | -11.03M | -11.70M | -11.99M |
| Income Before Tax | -10.47M | -10.12M | -10.40M | -11.03M | -11.22M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.47 | -10.12 | -10.40 | -11.03 | -11.22 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 86.00K | 89.00K | 92.00K | 101.00K | 104.00K |
| Net Income | -10.38M | -10.03M | -10.31M | -10.93M | -11.12M |
| EBIT | -10.98M | -10.68M | -11.03M | -11.70M | -11.99M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.31 | -0.30 | -0.32 | -0.34 | -0.34 |
| Normalized Basic EPS | -0.19 | -0.19 | -0.20 | -0.21 | -0.21 |
| EPS Diluted | -0.31 | -0.30 | -0.32 | -0.34 | -0.34 |
| Normalized Diluted EPS | -0.19 | -0.19 | -0.20 | -0.21 | -0.21 |
| Average Basic Shares Outstanding | 133.95M | 132.25M | 130.86M | 129.81M | 129.06M |
| Average Diluted Shares Outstanding | 133.95M | 132.25M | 130.86M | 129.81M | 129.06M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |